Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2020-12-18 Regulatory Filings
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Pharmicell regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약 체결). It details the contract value, counterparty (Sigma-Aldrich), and duration. Since it is a specific regulatory disclosure of a commercial contract and does not fit into categories like M&A or financial reports, it is classified as a general regulatory filing.
2020-12-18 Korean
투자판단관련주요경영사항
Legal Proceedings Report Classification · 95% confidence The document is a regulatory filing from Pharmicell regarding the approval of a Phase 3 clinical trial for 'Cellgram-LC' by the Ministry of Food and Drug Safety in South Korea. It details the trial's purpose, design, and timeline. Since it is a specific regulatory disclosure regarding business operations (clinical trial approval) that does not fit into categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2020-12-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. This is a standard regulatory filing in South Korea used by insiders (directors/executives) to disclose their personal share transactions (insider trading). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2020-11-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is required when an individual or entity's shareholding in a listed company crosses certain thresholds (typically 5%). It details the reporting person, special related parties, the number of shares held, and changes in ownership (in this case, a sale of shares by a special related party). This falls under the 'Major Shareholding Notification' category.
2020-11-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). It details the sale of shares by an executive (Kim Seong-nyun) of Pharmicell Co., Ltd. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents insider transactions by company management.
2020-11-20 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Changes in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) from Pharmicell Co., Ltd. It details specific transactions (sales) of shares by company executives and major shareholders, including the name of the individual (Kim Seong-nyeon), the date of the transaction, and the change in share count. This falls under the category of Major Shareholding Notification (MRQ) as it reports changes in significant share ownership levels and insider holdings.
2020-11-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.